ReviewFrontiers in chemistry2025
NIR-II fluorescence in lung cancer: advancing precision diagnosis and image-guided therapy.
Review in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in NIR-II Fluorescence Laparoscopy for Precision Diagnosis and Theranostics of Urological Oncology.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer ranks among the leading causes of cancer incidence and mortality worldwide. Conventional diagnostic and therapeutic approaches remain constrained by suboptimal sensitivity, exposure to ionizing radiation, and poor overall prognosis, driving efforts to develop novel diagnostic and therapeutic strategies to improve clinical outcomes. Second near-infrared window (NIR-II) fluorescence imaging offers deep tissue penetration and high spatial resolution; accordingly, a wide array of NIR-II fluorescent probes, imaging systems, and photointerventional therapies have been developed. In this review, we summarize recent advances and applications of NIR-II in lung cancer diagnosis and treatment and discuss the design and future directions of integrated diagnostic-therapeutic (theranostic) platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.